Compare Palantir Technologies Inc (PLTR) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Tilray Brands Inc — how do they compare? Palantir Technologies Inc trades at $205.58 (market cap $477.68B), while Tilray Brands Inc trades at $3.49 (market cap $530.54M). The key difference: Palantir Technologies Inc is far larger — about 900.4× Tilray Brands Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Tilray Brands Inc for 31 Days on average.
| PLTR | TLRY | |
|---|---|---|
Market Cap | $477.68B | $530.54M |
Volume | 41,744,992 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $207.18 | $21.00 |
52-Week Low | $107.27 | $3.57 |
Typical Hold Time | 78 Days | 31 Days |
Enterprise Value | $468.48B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $205.71, up 6.01% with strong bullish momentum. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025 and net income margin expanding to 36.3%. Technical indicators signal bullish sentiment with the price approaching resistance at $206. Recent partnership with Armada for sovereign AI infrastructure and consistent earnings beats highlight the company's growth trajectory.
Palantir presents compelling growth prospects driven by AI platform adoption, though premium valuations (P/E 169.9, P/S 83.02) warrant caution. Analyst consensus remains positive with 54% buy ratings and $191.69 price target. Key risks include valuation sensitivity and competitive pressures in the AI software space. The company's strong cash flow generation and expanding commercial customer base support long-term upside potential.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
